Company intelligence / Profile preview
SyntheX
San Francisco, California, United Statessynthexlabs.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
SyntheX has developed a proprietary cell-based synthetic biology drug discovery platform called ToRFLEx. This enables the identification of compounds that modulate challenging or "undruggable" protein targets by disrupting protein-protein interactions or inducing targeted protein degradation. The company's primary therapeutic area is oncology, with a pipeline focused on novel mechanisms such as synthetic lethality and oncogene addiction. Several programs are in preclinical or discovery stages; some earlier candidates have been discontinued.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Molecular gluesSmall moleculesPeptides and macrocycles (cell-based)
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Bristol Myers SquibbJLabs
Beyond the preview
Go deeper on SyntheX.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SyntheX.